Tag: Epclusa

While clinical trials for Epclusa (sofosbuvir/velpatasvir) did not identify hair loss as a reported common side effect, anecdotal evidence from some patients suggests otherwise. This article will address the pressing question, **Does Epclusa make your hair fall out?**, by examining the clinical data, potential underlying causes, and distinguishing it from older Hepatitis C treatments.

Initially approved by the FDA in 2014, Harvoni was a landmark hepatitis C treatment offering cure rates of over 90% for specific genotypes. While newer, more versatile direct-acting antivirals (DAAs) have since emerged, the question remains: **is Harvoni still used** in current medical practice? The answer is yes, though its place in therapy has evolved.

Globally, an estimated 50 million people have chronic hepatitis C [1.3.3]. The question 'What is the miracle drug for hep C?' points not to a single pill, but to a revolutionary class of drugs called Direct-Acting Antivirals (DAAs) that can cure more than 95% of cases [1.3.3].

Globally, an estimated 50 million people have chronic hepatitis C virus (HCV) infection. The answer to 'What is the new cure for hep C?' lies in direct-acting antiviral (DAA) medications, which can cure more than 95% of cases.

Recent years have seen a revolution in hepatitis C (HCV) treatment, with direct-acting antivirals (DAAs) now able to cure over 95% of cases. This has led many to wonder: what is the Hep C pill called? The answer is that there isn't just one pill, but a range of highly effective oral medications that target the virus directly.